Mastodon

Cicomin-Altfarm (Suppositories) Instructions for Use

Marketing Authorization Holder

Altpharm LLC (Russia)

ATC Code

B03BA01 (Cyanocobalamin)

Active Substance

Cyanocobalamin (Rec.INN registered by WHO)

Dosage Form

Bottle Rx Icon Cicomin-Altfarm Rectal suppositories 500 mcg: 10 pcs.

Dosage Form, Packaging, and Composition

Rectal suppositories 1 supp.
Cyanocobalamin 500 mcg

5 pcs. – contour cell packs (2) – cardboard packs.

Clinical-Pharmacological Group

B vitamin

Pharmacotherapeutic Group

Vitamins

Pharmacological Action

Vitamin B12 belongs to the group of water-soluble vitamins. It has high biological activity. It is necessary for normal hematopoiesis (promotes the maturation of erythrocytes).

It participates in the processes of transmethylation, hydrogen transfer, formation of methionine, nucleic acids, choline, and creatine. It promotes the accumulation of compounds containing sulfhydryl groups in erythrocytes.

It has a beneficial effect on the function of the liver and nervous system. It participates in the synthesis of the myelin sheath, stimulates hematopoiesis, reduces pain associated with peripheral nervous system damage, and stimulates nucleic acid metabolism through the activation of folic acid.

It activates the blood coagulation system; in high doses, it causes an increase in the activity of thromboplastin and prothrombin.

Pharmacokinetics

After oral administration, it is absorbed from the gastrointestinal tract. It is metabolized in tissues, converting into the coenzyme form – adenosylcobalamin, which is the active form of cyanocobalamin.

It is excreted in bile and urine.

Indications

Anemias due to B12-deficiency states; as part of combination therapy for iron deficiency and posthemorrhagic anemia; aplastic anemia caused by toxic substances and drugs; liver diseases (hepatitis, cirrhosis); funicular myelosis; polyneuritis; radiculitis; neuralgia; amyotrophic lateral sclerosis; cerebral palsy; Down syndrome; peripheral nerve injuries; skin diseases (psoriasis, photodermatoses, dermatitis herpetiformis, neurodermatitis); for the prevention and treatment of vitamin B12 deficiency symptoms (including when using biguanides, PAS, vitamin C in high doses); radiation sickness.

ICD codes

ICD-10 code Indication
B18 Chronic viral hepatitis
D50 Iron deficiency anemia
D51 Vitamin B12 deficiency anemia
D61 Other aplastic anemias
D62 Acute posthemorrhagic anemia
E53.8 Deficiency of other specified B group vitamins
G12.2 Motor neuron disease
G32.0 Subacute combined degeneration of spinal cord in diseases classified elsewhere
G62.9 Polyneuropathy, unspecified
G63.2 Diabetic polyneuropathy
G80 Cerebral palsy
K73 Chronic hepatitis, not elsewhere classified
K74 Fibrosis and cirrhosis of liver
L13.0 Dermatitis herpetiformis
L20.8 Other atopic dermatitis (neurodermatitis, eczema)
L28.0 Lichen simplex chronicus (circumscribed neurodermatitis)
L40 Psoriasis
L56.2 Photocontact dermatitis [berloque dermatitis]
M54.1 Radiculopathy
M54.3 Sciatica
M54.4 Lumbago with sciatica
M79.2 Neuralgia and neuritis, unspecified
Q90 Down syndrome
T14.4 Injury of nerve(s) of unspecified body region
T66 Unspecified effects of radiation (radiation sickness)
ICD-11 code Indication
1E51.Z Chronic viral hepatitis, unspecified
3A00.Z Iron deficiency anemia, unspecified
3A01.Z Megaloblastic vitamin B12 deficiency anemia, unspecified
3A70.Z Aplastic anemia, unspecified
3A94 Acute posthemorrhagic anemia
5B5E Folic acid deficiency
5B5F Vitamin B13 deficiency
5B5G Biotin deficiency
5B5H Pantothenic acid deficiency
5B5J Choline deficiency
5B7Z Malnutrition, unspecified
8B44.Y Other specified degenerative myelopathic disorders
8B60.Z Motor neuron disease, unspecified
8B6Y Other specified motor neuron diseases or related disorders
8B6Z Motor neuron diseases or related disorders, unspecified
8B93.Z Radiculopathy, unspecified
8C03.0 Diabetic polyneuropathy
8C4Z Disorders of nerve roots, plexuses or peripheral nerves, unspecified
8D2Z Cerebral palsy, unspecified
8E4A.1 Paraneoplastic or autoimmune diseases of the peripheral or autonomic nervous system
8E61.0 Radiation-induced brain injury
8E61.1 Radiation-induced spinal cord injury
9A06.70 Atopic eczema of the eyelids
DB93 Fibrosis or cirrhosis of liver
DB97.2 Chronic hepatitis, not elsewhere classified
EA80.0 Infantile atopic eczema
EA80.1 Childhood atopic eczema
EA80.2 Adult atopic eczema
EA80.Z Atopic eczema, unspecified
EA83.00 Lichen simplex of vulva
EA83.01 Lichen simplex of male genital organs
EA83.02 Lichen simplex of perianal area
EA83.0Z Lichen simplex of unspecified location
EA85.20 Atopic hand eczema
EA90.Z Psoriasis, unspecified
EB44 Herpetiform dermatitis
EK20 Photoallergic reaction to fragrances or cosmetic products
EM0Y Other specified diseases of the skin
FB56 Specified soft tissue diseases, not elsewhere classified
LD40.0 Down syndrome
ME84.20 Lumbago with sciatica
ME84.3 Sciatica
ND56.4 Injury of nerve of unspecified body region
NF00 Exposure to radiation, not elsewhere classified

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

It is administered orally, subcutaneously, intramuscularly, intravenously, and intralumbally. The dosage regimen is set individually, depending on the indications, clinical situation, patient’s age, and the dosage form used.

For anemias associated with vitamin B12 deficiency, 100-200 mcg is administered every other day. For anemia with signs of funicular myelosis and for macrocytic anemias with nervous system diseases – 400-500 mcg daily for the first 7 days, then once every 5-7 days.

During remission in the absence of signs of funicular myelosis, the maintenance dose is 100 mcg twice a month; in the presence of neurological symptoms – 200-400 mcg 2-4 times a month.

For acute posthemorrhagic and iron deficiency anemia – 30-100 mcg 2-3 times a week. For aplastic anemias (especially in children) – 100 mcg until clinical improvement. For nutritional anemia in young children and premature infants – 30 mcg/day for 15 days.

For diseases of the central and peripheral nervous system, neurological diseases with pain syndrome, it is administered in increasing doses – 200-500 mcg; upon improvement of the condition – 100 mcg/day. The course of treatment is 2 weeks. For traumatic lesions of the peripheral nervous system – 200-400 mcg every other day for 40-45 days.

For hepatitis and liver cirrhosis – 30-60 mcg/day or 100 mcg every other day for 25-40 days.

For dystrophies in young children, Down syndrome, and cerebral palsy – 15-30 mcg every other day.

For funicular myelosis, amyotrophic lateral sclerosis, it can be injected into the spinal canal at 15-30 mcg, gradually increasing the dose to 200-250 mcg.

For radiation sickness, diabetic neuropathy, sprue – 60-100 mcg daily for 20-30 days.

For vitamin B12 deficiency for prevention – intramuscularly or intravenously 1 mg once a month; for treatment – intramuscularly or intravenously 1 mg daily for 1-2 weeks, maintenance dose 1-2 mg intramuscularly or intravenously – from once a week to once a month. The duration of treatment is set individually.

Adverse Reactions

Possible allergic reactions, mental agitation, cardialgia, tachycardia, diarrhea, headache, dizziness; when used in high doses – hypercoagulation, purine metabolism disorder.

Contraindications

Hypersensitivity to cyanocobalamin; thromboembolism, erythremia, erythrocytosis; pregnancy, breastfeeding period.

With caution

Angina pectoris, benign and malignant neoplasms accompanied by megaloblastic anemia and cyanocobalamin deficiency, tendency to thrombosis.

Use in Pregnancy and Lactation

Contraindicated for use during pregnancy and breastfeeding.

Pediatric Use

Can be used in children according to indications, in recommended doses and regimens. It is necessary to strictly follow the instructions for medical use of cyanocobalamin preparations in children.

Special Precautions

During treatment with cyanocobalamin, peripheral blood picture and coagulation parameters should be regularly monitored.

Cyanocobalamin deficiency must be diagnostically confirmed before its prescription, as it may mask folic acid deficiency.

Antimetabolites and most antibiotics may affect the results of the quantitative determination of cyanocobalamin using microbiological methods.

Drug Interactions

With simultaneous use with oral hormonal contraceptives, a decrease in the plasma concentration of cyanocobalamin is possible.

With simultaneous use with anticonvulsants, the absorption of cyanocobalamin from the intestine is reduced.

With parenteral use, chloramphenicol may reduce the hematopoietic effect of cyanocobalamin in anemia.

With simultaneous use, aminoglycosides, salicylates, antiepileptic drugs, colchicine, potassium preparations, cimetidine, metformin, oral contraceptives, ranitidine, triamterene, methotrexate reduce the absorption of cyanocobalamin from the intestine.

Storage Conditions

Store at 2°C (36°F) to 15°C (59°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

TABLE OF CONTENTS